Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

A case report of reversible generalized seizures in a patient with Waardenburg syndrome associated with a novel nonsense mutation in the penultimate exon of SOX10

  • 1,
  • 2,
  • 3, 4,
  • 3, 4,
  • 5,
  • 1 and
  • 1, 2Email author
BMC Pediatrics201818:171

https://doi.org/10.1186/s12887-018-1139-2

  • Received: 13 June 2017
  • Accepted: 2 May 2018
  • Published:
Open Peer Review reports

Abstract

Background

Waardenburg syndrome type 1 (WS1) can be distinguished from Waardenburg syndrome type 2 (WS2) by the presence of dystopia canthorum. About 96% of WS1 are due to PAX3 mutations, and SOX10 mutations have been reported in 15% of WS2.

Case presentation

This report describes a patient with WS1 who harbored a novel SOX10 nonsense mutation (c.652G > T, p.G218*) in exon 3 which is the penultimate exon. The patient had mild prodromal neurological symptoms that were followed by severe attacks of generalized seizures associated with delayed myelination of the brain. The immature myelination recovered later and the neurological symptoms could be improved. This is the first truncating mutation in exon 3 of SOX10 that is associated with neurological symptoms in Waardenburg syndrome. Previous studies reported that the neurological symptoms that associate with WS are congenital and irreversible. These findings suggest that the reversible neurological phenotype may be associated with the nonsense mutation in exon 3 of SOX10.

Conclusions

When patients of WS show mild prodromal neurological symptoms, the clinician should be aware of the possibility that severe attacks of generalized seizures may follow, which may be associated with the truncating mutation in exon 3 of SOX10.

Keywords

  • SOX10
  • Waardenburg syndrome
  • Nonsense mutation
  • Delayed myelination
  • Seizure attack

Background

Waardenburg syndrome (WS) is a hereditary disease characterized by sensorineural hearing loss and pigmentation abnormalities. WS has been classified into four subtypes on the basis of the clinical symptoms, namely, WS1 to WS4 [1]. Mutations in six genes (PAX3, MITF, EDN3, EDNRB, SOX10, and SNAI2) have been reported as the cause of WS [1].

Mutations in SOX10 were first reported to associate with WS4 and then later with WS2. WS4 can be accompanied by neurological symptoms, in which case it is called PCWH (Peripheral demyelinating neuropathy, Central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease, OMIM: #609136) [2]. While WS2 can also be accompanied by neurological symptoms, only six cases have been reported to date [35]. Those reports suggest that the neurological symptoms that associate with WS are congenital and irreversible.

In this report, we describe the case of a patient with WS1 who harbored a de novo SOX10 heterozygous nonsense mutation. The patient had mild prodromal neurological symptoms that were followed by an attack of generalized seizures that associated with delayed myelination of the brain which recovered later.

Case presentation

A 5-month-old boy was referred to our hospital with the chief complaint of congenital deafness. No abnormalities were observed during his perinatal course. However, at presentation, his motor development was delayed: he was still unable to hold up his head. He also showed bilateral congenital horizontally narrow eyes with drooping eyelids (blepharoptosis), heterochromia iridis, and dystopia canthorum (W-index: 2.24) (Fig. 1a). Interview and visual inspection did not find musculoskeletal abnormalities or limits of mobility in the limbs. His defecation was normal and no intestinal signs indicating constipation, disorder of peristalsis, or obstruction were apparent by interview and auscultation. Oto-acoustic emission, conditioned orientation response audiometry, and auditory brainstem response revealed severe hearing loss (Additional file 1). Computed tomography of the temporal bone revealed hypoplasia of the semicircular canals and cochlea in the bilateral ears (Additional file 2). None of the members of his family had any of the symptoms found in the proband (Additional file 3).
Fig. 1
Fig. 1

Clinical features of the patient. a The face at 5 months of age. The patient had blue irides, blepharoptosis, and dystopia canthorum (W-index: 2.24). b-e Brain MRI findings at 8 and 18 months of age. At 8 months of age, namely, 3 months after the proband had a 4-min-long systemic clonic seizure, T1- b and T2-weighted images c demonstrated delayed myelination of the frontal lobe. In normal development, myelination of frontal lobe is observed at 3–4 months of age on T1-weighted imaging, and at 7–8 months of age on T2-weighted imaging. Follow-up MRI performed at 18 months of age demonstrated almost normal myelination on T1-weighted imaging d and T2-weighted imaging e

At 5 months of age, the proband developed an attack of generalized seizures. Initially, the seizures lasted for a few seconds and occurred once a day. In the following 2 weeks, both the frequency and duration of the seizures increased. 2 weeks after the seizures started, the proband had a systemic clonic seizure that lasted for about 4 min and the next day he had a longer clonic seizure with eye deviation to the right for about 12 min. Although obvious abnormal findings were not observed in the electroencephalogram, epilepsy was suspected. Sodium valproate was started 3 days after the 4-min-long seizure. Since then, the seizures have stopped for 3 years even after sodium valproate was stopped 2 years after the start of prescription. At the age of 12 months, he started holding up his head on his own, and, at 16 and 20 months, he started pulling up on things and walking along against a wall, respectively. Magnetic resonance imaging (MRI) performed at 8 months of age revealed delayed myelination of the frontal lobe on both T1- and T2-weighted imaging (Fig. 1b and c). However, follow-up MRI performed at 18 months of age demonstrated almost normal myelination (Fig. 1d and e).

Genomic DNA was extracted from whole blood and subjected to whole exome sequencing analysis using SureSelect Human All Exon V5 (Agilent Technologies, CA, USA). The captured DNA was subjected to the massively parallel sequencing system (HiSeq2000, Illumina, CA, USA). Paired-end read sequences were mapped and quality-checked with StrandNGS (Strand Genomics, CA, USA) using the reference sequence hg19/GRCh37. Among 88,273 variants detected in the patient and parents, 263 variants predicted to affect amino acid residues and detected in the patient with minor allele frequency (MAF) < 0.5% in public databases [69] were extracted and proceeded for segregation analysis within the family. Finally, eight variants of seven genes were selected as possible pathogenic mutations (Additional file 4). Of these, the SOX10 mutation (c.652G > T, p.G218*) was absent from public databases, i.e. novel. SOX10 has been previously reported as a responsible gene for PCWH, WS 2E (OMIM: #611584), and 4C (#613266). Since multiple nonsense mutations of SOX10 have already been reported to cause PCWH or WS2/4 [2], the mutation detected in this case was also considered a pathogenic mutation. The heterozygous nonsense mutation in SOX10 was in exon 3 (Additional file 5). Sanger sequencing validated the presence of the mutation in the proband, and the mutation was not present in his parents (Additional file 6).

Discussion

WS1 can be distinguished from WS2 by the presence of dystopia canthorum [1]. About 96% of cases of WS1 are due to PAX3 mutations [2, 3]. It has been suggested that about 3% of cases who were not associated with mutations in PAX3 had W-index scores that were diagnostic of WS1 [10]. Indeed, although our proband was clinically classified as having WS1, whole exome sequencing did not reveal any mutation in PAX3; instead, a novel SOX10 mutation was found. These findings suggest that SOX10 mutations are one of the causes of WS1.

Truncating mutations often inactivate gene function, either because they produce truncated protein products or because there is a significant decrease in cytoplasmic mRNA abundance by nonsense-mediated mRNA decay (NMD). When a truncating mutation occurs at a nucleotide located in the last coding exon or less than 50–55 nucleotides upstream of the last coding exon, the truncated mRNA is not recognized and the NMD is escaped [11]. Then, the mutant protein is synthesized and acts as a dominant negative protein that impairs the function of the wild-type SOX10, resulting in the neurological phenotypes [12, 13]. To date, the neurological symptoms associated with SOX10 have been reported only in the patients with truncating mutations in the last exon (exon 4 in NM_006941) of SOX10 [9]. The present patient had a novel nonsense mutation in exon 3, 45 nucleotides upstream from the 5′ end of exon 4. Thus, this is the first case to show the neurological phenotypes due to the nonsense mutation in exon 3 of SOX10 (Additional file 5).

Previous reports stated that the neurological symptoms of WS due to delayed myelination are congenital and irreversible [35]. However, the present report suggests that, while patients with a nonsense mutation in SOX10 that is proximal to the 3′ end of exon 3 can also exhibit delayed myelination, they may develop severe attacks of generalized seizures that can be improved because the immature myelination can recover later. Long-term follow-up is required for these patients because recurrence of seizure attacks may occur in the future. These findings suggest that they may be clinical characteristics of WS that arise from a nonsense mutation in exon 3 of SOX10. It is also possible to speculate that modifier genes that complement or repair immature myelination played a role. In conclusion, when patients of WS show mild prodromal neurological symptoms, such as delayed motor development and/or blepharoptosis, the clinician should be aware of the possibility that severe attacks of generalized seizures may follow, which may be associated with the truncating mutation in exon 3 of SOX10.

Abbreviations

MRI: 

Magnetic resonance imaging

NMD: 

nonsense-mediated mRNA decay

PCWH: 

Peripheral demyelinating neuropathy, Central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease

WS: 

Waardenburg syndrome

Declarations

Acknowledgements

The authors thank the family for their cooperation.

Funding

This study was supported by a Grant-in-Aid for Clinical Research (H27-NHO (kankaku)-02) from the National Hospital Organization (to T. M.) and a Health Labour Sciences Research Grant (H26-Nanchito (Nan)-Ippan-035) from the Ministry of Health, Labour, and Welfare of Japan (to T. M.). The grants were spent for collection, analysis, publication for the manuscript, and personnel expenses. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets generated or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

NS and TM are responsible for general conception and design, and performed interpretation of clinical data and drafted the manuscript. HM, FM, and TT carried out the genetic analysis and helped to draft the manuscript. HT and NM are responsible for clinical data collection. TM finished the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by ethical committees of National Center for Child Health and Development, National Hospital Organization Tokyo Medical Center, Tokyo Medical and Dental University, and RIKEN Center for Integrative Medical Sciences. All the procedures were conducted after obtaining a written informed consent from the parents of the child. The other members of the family were not subjected for genetic analysis, therefore informed consent forms were not obtained.

Consent for publication

All authors, participants and parents agreed the publication of data presented in this manuscript. Written informed consent was obtained from the parents of the child to publish this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Otolaryngology, National Center for Child Health and Development, Tokyo, Japan
(2)
Division of Hearing and Balance Research, National Institute of Sensory Organs/ Medical Genetics Center, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro, Tokyo 152-8902, Japan
(3)
Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
(4)
Laboratory for Medical Science Mathematics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
(5)
Devision of Neurology, National Center for Child Health and Development, Tokyo, Japan

References

  1. Read AP, Newton VE. Waardenburg syndrome. J Med Genet. 1997;34:656–65.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet. 2004;36:361–9.View ArticlePubMedGoogle Scholar
  3. Bondurand N, Dastot-Le F, Stanchina L, Collot N, Baral V, Marlin S, et al. Deletions at the SOX10 gene locus cause Waardenburg syndrome types 2 and 4. Am J Hum Genet. 2007;81:1169–85.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Chaoui A, Watanabe Y, Touraine R, Baral V, Goossens M, Pingault V, et al. Identification and functional analysis of SOX10 missense mutation in different subtypes of Waardenburg syndrome. Hum Mutat. 2011;32:1436–49.View ArticlePubMedGoogle Scholar
  5. Sznajer Y, Coldéa C, Meire F, Delpierre I, Sekhara T, Touraine RL. A de novo SOX10 mutation causing severe type 4 Waardenburg syndrome without Hirschsprung disease. Am J Med Genet A. 2008;146:1038–41.View ArticleGoogle Scholar
  6. Database of Single Nucleotide Polymorphisms (dbSNP). http://www.ncbi.nlm.nih.gov/snp/. Accessed 16 Dec 2016.
  7. 1000Genomes. http://www.1000genomes.org. Accessed 16 Dec 2016.
  8. NHLBI Exome Variant Server (ESP6500). http://evs.gs.washington.edu/EVS/. Accessed 16 Dec 2016.
  9. Human Genetic Variation Database (HGVD). http://www.genome.med.kyoto-u.ac.jp/SnpDB/index.html. Accessed 16 Dec 2016.
  10. Farrer LA, Arnos KS, Asher JH Jr, Baldwin CT, Diehl SR, Friedman TB, et al. Locus Heterogeneity for Waardenburg Syndrome Is Predictive of Clinical Subtypes. Am J Hum Genet 1994;55:728–737.Google Scholar
  11. Kervestin S, Jacobson ANMD. A multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012;13:700–12.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Pingault V, Girard M, Bondurand N, Dorkins H, Van Maldergem L, Mowat D, et al. SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism. Hum Genet. 2002;111:198–206.View ArticlePubMedGoogle Scholar
  13. Inoue K, Shilo K, Boerkoel CF, Crowe C, Sawady J, Lupski JR, et al. Congenital hypomyelinating nuropathy, central dysmyelination, and Waardenburg-Hirschsprung disease: phenotypes linked by SOX10 mutation. Ann Neurol. 2002;52:836–42.View ArticlePubMedGoogle Scholar

Copyright

Advertisement